Vaxinano is a clinical-stage biotechnology company that is dedicated to the development of a new generation of nasally administered vaccines. The company's slogan, "Developing life-changing vaccines and immunotherapies," encapsulates their mission to combat infectious diseases and new pandemics in a more efficient and rapid manner. Founded in 2016, Vaxinano's approach is based on STELLAR-NP nanoparticles that provide a stable, adjuvant-free solution for an effective and long-lasting immune response against challenging pathogens such as parasites, viruses, and bacteria.
The company operates in the Biotechnology, Pharmaceutical, Logistics, and Delivery industries, reflecting its multidisciplinary approach to addressing healthcare challenges. Vaxinano's last reported investment was a non-equity assistance investment on 10 December 2016, with Eurasante listed as the investor. This signifies a strategic partnership and validation of Vaxinano's innovative vaccine technology. With its pioneering approach and support from investors, Vaxinano is positioned to make crucial advancements in vaccine development and contribute to global health security.
